Kenneth Cusi
Endocrinology, Diabetes & Metabolism · Gainesville, FLNPI 1770690752
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $236,606 of the $287,235 with a category attached, or 82.4%. 23 manufacturers reported payments, led by Novo Nordisk at 24.9% of the total. Among endocrinology, diabetes & metabolism clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 173 payments — averaging $1660.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$72K
- Boehringer Ingelheim$51K
- Novo Nordisk AS$35K
- GSK$17K
- Merck$15K
- Eli Lilly$13K
- plus $84K from 17 others
Across 283 payments — averaging $5805.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$1.2M
- Novo Nordisk AS$330K
- Merck$68K
- Boehringer Ingelheim International GmbH$36K
- Eli Lilly$19K
- Novartis$1K
What the payments were for
- Consulting fees$236,60682%
- Speaking & faculty fees$18,5756%
- Travel & lodging$29,21410%
- Food & beverage$2,8081%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 47 | $71,656 |
| Boehringer Ingelheim | 39 | $51,460 |
| Novo Nordisk AS | 10 | $34,957 |
| GSK | 6 | $17,004 |
| Merck | 11 | $15,050 |
| Eli Lilly | 3 | $12,705 |
| E.r. Squibb & Sons, L.L.C. | 15 | $12,111 |
| AstraZeneca | 5 | $10,925 |
| Gilead | 3 | $9,130 |
| Boehringer Ingelheim International GmbH | 2 | $8,300 |
| Siemens Medical Solutions USA, Inc. | 10 | $7,917 |
| Dexcom, Inc. | 5 | $6,634 |
| Janssen Research & Development, LLC | 5 | $6,359 |
| Amgen | 2 | $4,248 |
| AbbVie | 1 | $4,000 |
| Hikma Pharmaceuticals USA | 1 | $4,000 |
| Zealand Pharma A/s | 2 | $3,710 |
| Intercept Pharmaceuticals, Inc. | 1 | $3,000 |
| Theratechnologies Inc. | 1 | $2,000 |
| Coherus Oncology, Inc. | 1 | $1,000 |
| Boehringer Ingelheim S.A. | 1 | $900 |
| Janssen Scientific Affairs, LLC | 1 | $134 |
| La Jolla Pharmaceutical Company | 1 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$287,235 in reported general payments places this provider in the 95th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 11 | $10,488 |
| Pioglitazone Hcl | 12 | $178 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $51,460 | $10,48811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Gainesville
- Jay SkylerMiami$2.2M
- Arelis MaderaPort Charlotte$1.7M
- Damon TantonOrlando$1.2M
- Gaston PonteMelbourne$906K
- Brian LakeLargo$888K
- David SuttonJacksonville$783K
- Mae Sheikh AliJacksonville$751K
- Richard PratleyOrlando$735K
- Lee MetchickDeland$728K
- Misha DenhamCoral Gables$673K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.